Xenpozyme 20 mg (Olipudase Alfa POWDER FOR SOLUTION) 20 MG

Xenpozyme 20 mg is a powder for solution containing olipudase alfa, used for enzyme replacement therapy. This intravenous medication is manufactured by Sanofi-Aventis Canada Inc.

Strength

20 MG

Manufacturer / TM Owner

SANOFI-AVENTIS CANADA INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Xenpozyme 20 mg is primarily used for enzyme replacement therapy. It is designed to address certain metabolic disorders by providing the necessary enzymes that the body may lack. Patients often inquire about what Xenpozyme is used for, and it is generally utilized to manage conditions related to enzyme deficiencies.

Side Effects

Common effects of Xenpozyme 20 mg may include reactions at the injection site, such as redness or swelling. Some individuals might experience flu-like symptoms or mild gastrointestinal discomfort. These effects can vary among users and are not exhaustive.

Precautions & Warnings

Xenpozyme 20 mg should be handled with care, ensuring proper storage and preparation. It is crucial to follow healthcare provider instructions for administration. Patients with known allergies to any components should exercise caution and consult their healthcare provider before use.

Avoid Interactions

Xenpozyme 20 mg may interact with other medications, particularly those that affect the immune system or blood clotting. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also influence its effectiveness.

Frequently Asked Questions

Xenpozyme 20 mg is used for enzyme replacement therapy to address certain metabolic disorders.

Xenpozyme 20 mg is administered intravenously as a powder for solution.

Common side effects may include reactions at the injection site, flu-like symptoms, and mild gastrointestinal discomfort.

Xenpozyme 20 mg may interact with other medications, so it is important to consult a healthcare provider before combining it with other treatments.

Xenpozyme 20 mg is manufactured by Sanofi-Aventis Canada Inc.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.